Details for Patent: 8,722,693

Title:	Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile
Abstract:	The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	Rodgers; James D. (Landenberg, PA), Li; Hui-Yin (Hockessin, DE)
Assignee:	Incyte Corporation (Wilmington, DE)
Filing Date:	Dec 05, 2013
Application Number:	14/097,588
Claims:	1. A (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclop- entylpropanenitrile phosphoric acid salt. 2. A drug product comprising (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile phosphoric acid salt and a pharmaceutically acceptable carrier. 3. The drug product of claim 2, wherein the drug product is suitable for oral administration. 4. The drug product of claim 2, wherein the drug product is in tablet form. 5. A crystalline (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile phosphoric acid salt. 6. The crystalline salt of claim 5, wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile:phosphoric acid salt. 7. A drug product comprising a crystalline (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile phosphoric acid salt and a pharmaceutically acceptable carrier. 8. The drug product of claim 7, wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile:phosphoric acid salt. 9. The drug product of claim 7, wherein the drug product is suitable for oral administration. 10. The drug product of claim 7, wherein the drug product is in tablet form.